Minireview: Antioxidant Vitamin Supplementation in Cardiovascular Diseases

Available online at www.annclinlabsci.org 89 Annals of Clinical & Laboratory Science, vol. 37, no. 1, 2007 Minireview: Antioxidant Vitamin Suppleme...
Author: Darlene Ford
19 downloads 0 Views 133KB Size
Available online at www.annclinlabsci.org

89

Annals of Clinical & Laboratory Science, vol. 37, no. 1, 2007

Minireview: Antioxidant Vitamin Supplementation in Cardiovascular Diseases

Graziano Riccioni,1 Tonino Bucciarelli,2 Barbara Mancini,2 Francesco Corradi,1 Carmine Di Ilio,2 Peter A. Mattei,3 and Nicolantonio D’Orazio2 1Cardiology Unit, San Camillo de Lellis Hospital, Manfredonia, Foggia, Italy; 2Human Nutrition, and 3Laboratory of Biostatistics, Biomedical Sciences Department; G. D’Annunzio University, Chieti, Italy. Abstract. Cardiovascular disease is the most important adult health problem in wealthy countries, where biological factors such as obesity, hypertension, dyslipidemia, diabetes, inappropriate diet, cigarette smoking, and sedentary life-style have contributed to its dissemination. Research concerning nutritional regimens has shown that persons who consume large amounts of fruit and vegetables have lower incidences of cardiovascular diseases, stroke, and tumors, although the precise mechanisms for this protective effect are elusive. Possible explanations include (a) increased consumption of dietary fiber, (b) reduced consumption of dietary cholesterol and other lipids, and (c) increased intake of the antioxidant vitamins (A, C, and E). Numerous studies have raised the question whether vitamin supplements help to prevent cardiovascular diseases. Results of randomized controlled trials of antioxidant vitamin supplements in large numbers of participants has been ambiguous or contradictory. This minireview examines the relevant clinical reports on dietary supplements of vitamins A, C, and E to determine whether they support the premise that patients at risk of cardiovascular disease may be candidates for this therapeutic option. Keywords: vitamins A, C, E, acute coronary syndrome, acute myocardial infarction, angina pectoris, cardiac ischemia, antioxidant dietary supplements Observational studies have demonstrated that acute coronary syndromes (ACS), in particular unstable angina (UA) and acute myocardial infarction (AMI), share a common anatomical foundation. These various clinical manifestations derive from a basic pathophysiologic mechanism that consists of the erosion or breach of an atherosclerotic plaque; moreover, many thrombotic phenomena are associated with this event [1-3]. ACS are the consequence of acute or sub-acute primary oxygen deficit to the myocardium, which can result from erosion of a atherosclerotic plaque, inflammatory phenomena, thrombosis, vasoconstriction, or micro-embolization. The Euro Heart Study, conducted from September 2000 to May 2001 in Address correspondence to Graziano Riccioni, M.D., PhD., Via G. De Rogatis 12, CP 188, San Severo (FG) 71016, Italy; tel 39 333 636 6661; fax 39 088 222 7022; e-mail griccioni@ hotmail.com.

103 medical centers in 25 European countries, reported 12% mortality within 6 mo for patients with ACS who did not show an elevation of the ST segment [4]. This study suggested that long-term results might be improved in selected patients by a clinical strategy that includes careful stratification of the risks, administration of innovative drugs, and revascularization procedures. The principal cardiovascular diseases (CVD) include cardiac ischemic disease (CHD) with its clinical manifestations (AMI, angina pectoris, and sudden death), cerebrovascular diseases (stroke and transitory ischemic attack), and peripheral vasculopathies. Intensive efforts of researchers during the past 50 years have been concentrated on CHD, which represents 30-50% of the total prevalence of CVD [5]. In the last 30 years, mortality from CHD has been reduced by 50% [10,11], although CHD

0091-7370/07/0100-0089. $1.75. © 2007 by the Association of Clinical Scientists, Inc.

90

Annals of Clinical & Laboratory Science, vol. 37, no. 1, 2007

remains the main cause of unexpected death in the United States (approximately 500,000 deaths/yr) and Europe (approximately 400,000 deaths/yr). Mortality associated with CHD is attributed to AMI (60%), chronic coronary insufficiency (22%), and unexpected death (18%). A meta-analysis of world-wide mortality showed that the main causes were cerebrovascular disease, respiratory infections, neonatal diarrhea, chronic obstructive pulmonary disease, tuberculosis, varicella, accidents, and respiratory tract tumors [6]. People at risk for primary and secondary CVD appear less likely to use dietary supplements, despite the possible benefits shown in clinical trials [7]. Therefore, guidelines are needed for the general public and health professionals regarding the uncontrolled use of dietary supplements [7]. The current evidence does not support indiscriminate use of vitamins A, C, E, or β-carotene to prevent or reduce CVD. In fact, some studies of oral antioxidant supplementation have noted harmful effect in some people [8-10]. The aim of this paper is to review published works with results that support, confirm, or contradict the postulated protective role of antioxidant vitamins in CVD. Nutrition and atherosclerosis. Proper nutrition could be considered as non-pharmacological prevention and therapy of ischemic disease. Nutrition is important in both primary and secondary prevention, as many cardiovascular, hepatic, and renal diseases are secondary to qualitatively and quantitatively inappropriate diet and life-style [11]. Dietary practices influence the pathogenesis of atherosclerotic plaques through direct influence on the determinants of atherosclerotic processes, such as plasma lipid accumulation (triglycerides, HDL- and LDL-cholesterol, phospholipids), structural integrity of circulating lipids (oxidized-LDL), levels of plasma antioxidants, production of free radicals, homocysteinemia, hyperglycemia, blood pressure, platelet aggregation, and lipid peroxidation [8,9]. Antioxidant vitamins. Numerous in-vivo and invitro studies indicate that the atherosclerotic processes (including endothelial damage and proliferation, and the production of foam cells)

depend in part on the peroxidative state of LDL. Antioxidant vitamins are one of the main defense mechanisms of the body’s non-enzymatic antioxidant systems. Ascorbic acid (vitamin C), alphatocopherol (the principal constitutent of vitamin E), and beta-carotene (pro-vitamin A) are the most studied natural antioxidants. Large-scale clinical trials have been conducted to determine whether vitamin supplements with antioxidant action decrease the risk of cardiovascular diseases. Some experimental and epidemiological studies seem to indicate beneficial effects of antioxidant vitamin supplementation on the development and progression of atherosclerotic plaques, resulting in reduction of cardiovascular events. However, a recently published study with well-defined primary and secondary prevention endpoints does not support this hypothesis [12]. Vitamin A. Vitamin A, the first fat-soluble vitamin to be identified, has 3 active forms: retinol, retinal, and retinoic acid; collectively called retinoids. The most important of these is beta-carotene, which has a high antioxidant effect [13,14]. The carotenoids have an important antioxidant role in quenching free radical reactions, particularly those involving singlet oxygen. This prevents damaging chain reactions that cause lipid peroxidation and damage to DNA, both of which are postulated precursors of atherosclerotic processes [15,16]. Vitamin A and carotenoids may have effects in various human diseases such as diarrhea, acute respiratory infections, ischemic heart disease, immunological disorders, and bronchial asthma [17]. Many trials have considered the effects of vitamin A dietary supplements on cardiovascular events and have yielded contradictory results. The Nurses Health Study (NHS), an epidemiological study conducted in the USA on 34,486 women, evaluated through a questionnaire the effect of the addition of vitamin A to regular diets. No association was seen between dietary supplements of vitamin A and the risk for coronary disease [18]. Several randomized controlled studies reported similar results. In the Physicians Health Study (PHS), a randomized, prospective, double-blind, placebo-controlled study of 22,071 physicians, the oral supplementation of beta-carotene (50 mg on

Antioxidant vitamin supplementation in cardiovascular diseases

alternating days; 12 yr follow-up), did not show a significant difference between the treated and control groups in respect to cardiovascular mortality [19]. In another study, 5 major carotenoids (alphaand beta-carotene, beta-cryptoxanthin, lutein, and lycopene) did not show protective effects against AMI [20]. The Beta Carotene and Retinol Efficacy Trial (CARET), a prospective, randomized, placebo-controlled 4-yr study of 18,314 smokers, was interrupted at 21 mo before its planned termination because patients treated with a combination of beta-carotene and vitamin A showed increased relative risk for lung cancer and cardiovascular mortality [21]. The Alpha Tocopherol Beta Carotene Cancer Prevention (ATBC) study, which evaluated beta-carotene (20 mg/day) supplementation in 1,862 male smokers with a previous MI, did not show any significant effect on cardiac-related mortality [22]. Vitamin C. Vitamin C, an important water-soluble substance, has 2 biologically active forms: ascorbic acid and dehydroascorbic acid. Dietary vitamin C is mostly supplied by fruits and vegetables. Its biological role is related to its reducing capability; ascorbate is readily oxidized to dehydroascorbate. Vitamin C acts as a hydrogen donor to reverse oxidation and hence is termed an antioxidant, which can inactivate free radicals before they damage proteins or lipids [16]. The First National Health and Nutrition Examination Survey (NHANES) epidemiological follow-up study in 11,348 subjects, age 25 - 74 yr, reported that individuals who received a high dose of vitamin C (>50 mg/day) had lower overall total mortality rate after 10 yr, and in particular lower mortality from cardiovascular disease [23]. The Health Professionals Follow-up Study reported that a relationship between vitamin C intake and major coronary events did not exist, although subjects whose vitamin C intake exceeded 50 mg/day had a lower rate of death from all cardiovascular diseases [24]. Vitamin C’s antioxidant action, which is more effective than that of vitamin E or beta-carotene, was considered as a possible mechanism of vascular protection. Joshipura et al [25] conducted a prospective cohort study in a population of 54,251 women and

91

42,148 men who were followed for 8 yr and were free of cardiovascular disease, cancer, and diabetes. The authors found that the consumption of fruits and vegetables, particularly green leafy vegetables and vitamin C-rich fruits and vegetables, appeared to have a protective effect against coronary heart disease (ie, nonfatal AMI or fatal coronary heart disease). However, subsequent reviews and metaanalyses of the relationship between antioxidants and atherosclerotic cardiac disease did not confirm these findings. An analysis of 2 studies, the Nurses Health Study (NHS) and Health Professional’s Follow-up Study, showed unclear reduction of prevalence and mortality from cardiovascular disease [26]. Increased production of free radicals derived from exposures to tobacco smoke, radiation, stress, insufficient physical activity, hypocaloric diets, drugs, and toxic substances evidently increases the need for vitamin C intake [27,28]. Two studies provide evidence contrary to the protective effects of vitamin C. Kushi et al [18] in the NHS epidemiogical study found no relationship between vitamin C intake and major coronary events. Kinlays et al [29] conducted a double-blind, randomized, placebo-controlled trial of vitamin C (1 g/day) supplement for 6 mo in 30 subjects with coronary artery disease. They found that such longterm oral vitamin C supplements did not improve key mechanisms of atherosclerosis or endothelial dysfunction, nor reduce LDL oxidation in vivo. Vitamin E. Vitamin E is an important antioxidant vitamin, playing an essential protective role against free radical damage [30,31]. Vitamin E comprises a group of substances belonging to 2 closely related families: tocopherols and tocotrienols, each existing in a number of isomeric forms: alpha, beta, gamma, and delta. The form that accounts for 90% of the vitamin activity in tissues is alpha-tocopherol [32,33]. The chemical structure of tocopherols and tocotrienols (which have an -OH group on the ring structure) makes them effective hydrogen donors. In donating hydrogen, vitamin E becomes oxidized, preventing the oxidation of metabolically more important substances, for example polyunsaturated fatty acids (PUFA) in cell membranes. This is important when free radicals are present, as these highly reactive substances can attack double bonds,

92

Annals of Clinical & Laboratory Science, vol. 37, no. 1, 2007

initiating chain reactions that generate more free radicals. When fatty acids are damaged, lipid peroxides are produced that can alter the function of the cell membrane and cause irreversible damage to metabolic pathways [34-37]. The nutritional requirement for vitamin E (10 mg/day) varies with the dietary intake of PUFA. Vitamin E is the most fat-soluble vitamin and is the major vitamin component in cell membranes and circulating lipoproteins. For this reason, vitamin E is the main antagonist of lipid peroxidation. Its protection of membranes is important for proper functioning of the vascular endothelial barrier, for reduction of proliferation stimuli for myocytes of the tunica media, and for decrease in chemotactic factors for monocytes [38]. The protective role of vitamin E for the endothelium is supported by a stimulatory action on the synthesis of PGI2, a vasodilator and platelet anti-aggregating agent [39]. Due to its fat solubility, vitamin E persists in membrane lipoproteins for long periods and, therefore, its dietary supplementation may not require daily dosing [40]. The Physicians Health Study (PHS) reported a prospective nested case-control study of 531 male physicians diagnosed with AMI, without prior history of cardiovascular disease, paired with control subjects and matched for age, smoking habit, and plasma levels of alpha- and gammatocopherol [20]. The results indicated that the men with higher plasma levels of gamma-tocopherol tended to have increased risk of AMI. In the Nurses Health Study (NHS), Kushi et al [18] found that vitamin E supplements of 100-250 UI/day reduced by 35 - 40% the incidence of major coronary events (nonfatal myocardial infarction and death from cardiac causes) among subjects in the highest quintile of vitamin E intake, over a follow-up period of 4 – 8 yr, compared to those in the lowest quintile. The benefit was greatest in subjects taking 100 to 250 UI of supplemental vitamin E per day, with little further benefit at higher doses [18]. In the Cambridge Heart Antioxidant Study (CHAOS), a randomized. controlled study of 2,002 patients with coronary artery disease (CAD), vitamin E supplements (400-800 UI/day) reduced the incidence of death from cardiovascular diseases and AMI [38]. In the Alpha–Tocopherol Beta

Carotene Cancer Prevention (ATBC) trial, the group of patients treated with alpha-tocopherol supplement (50 mg/day) showed a lower number of non-fatal AMI, but no reduction of the primary study end-points (that is, cardiovascular death and AMI) [22]. In the Secondary Prevention using Antioxidants of Cardiovascular Disease in Endstage renal disease (SPACE) trial, 196 patients with pre-existing cardiovascular disease and undergoing chronic haemodialysis were enrolled in a double-blind randomized controlled study (97 patients received vitamin E supplement (800 UI/ day) and 99 patients received a placebo) [41]. There was significant reduction of the primary end-points (fatal and non-fatal AMI, ischemic stroke, peripheral vascular disease, and unstable angina (UA) in subjects receiving the high dose vitamin E supplement [41]. The Prevention Study of the Italian Group for the Study of Survival in Myocardial Infarction (GISSI) reported that vitamin E supplements (300 mg/day) were associated with a non-significant reduction of total mortality (relative risk 0.86; p = 0.081) [42]. The Heart Outcomes Prevention Evaluation Study (HOPE) did not demonstrate the benefits reported by SPACE in the use of vitamin E at a dose of 400 UI/day [43]. Discussion The possible anti-atherogenic role of compounds with antioxidant characteristics depends on the various effects that free radicals can have on pathological and physiological processes. LDLoxidation has a key role in the activation and facilitation of atherogenesis. Antioxidants are capable of preventing the oxidative catabolism of nitric oxide (NO), a molecule with numerous beneficial effects. A discrepancy exists between the results derived from observational studies and randomized trials with vitamin supplements. In observational studies with coronary end-points, subjects with elevated plasma levels of antioxidants were protected from clinical complications of coronary disease (AMI and angina), whereas subjects treated with antioxidants in the interventional studies did not show protection against coronary disease [44].

Antioxidant vitamin supplementation in cardiovascular diseases

In studies with vitamin A supplements, there is no evidence for a protective effect against AMI. In a study of beta-carotene, a higher incidence of coronary events was observed in the group that received supplements compared to a control group. The mechanisms whereby fruits and vegetables protect against CVD are likely to be multiple. The postulated beneficial components of fruits and vegetables include antioxidant vitamins, particularly vitamin C, folate, fiber, minerals, and potassium. These dietary constituents can significantly increase the antioxidant capacity of serum and protect against in vivo lipoperoxidation. Several large-scale, double-blind, placebocontrolled trials have clearly shown that vitamin E, alone or in combination with other antioxidant vitamins, reduces the risk of fatal or nonfatal AMI in populations with CHD. Two end-point trials of vitamin E, though with much smaller patient populations, reported positive results (the SPACE and CHAOS studies). Descriptive, case-control, and prospective cohort studies have shown inverse associations between the frequency of CAD and dietary intake of antioxidant vitamins. In contrast, randomized therapeutic trials have thus far shown a lack of benefit with beta-carotene and a possible benefit with vitamin E. As oxidative stress is involved in the pathogenesis of atherosclerosis, during the past few years a variety of substances with antioxidant actions have been evaluated in clinical studies for primary and secondary prevention of CVD. The initial promising reports on beneficial effects with antioxidant therapies against atherosclerosis, derived from observational studies, were followed by generally negative results reported from large randomized controlled trials. For this reason, at the moment, treatment with antioxidant vitamins (A, C, and E) is not recommended for the prevention or treatment of CAD. Thus, the United States Preventive Services Task Force (USPSTF) concluded that the evidence currently available is insufficient to recommend the routine use of these supplements [45]. Although scientific rationale and observational studies are convincing, randomised primary and secondary intervention trials have failed to show any consistent benefit from the use of antioxidant

93

supplements on CVD, and some trials suggested possible harmful effects in certain subgroups of patients. Trials that investigate the effect of a balanced combination of antioxidants at levels achievable by diet are clearly needed [46]. New strategies are needed to clarify the exact role that antioxidants may have on the prevention of atherosclerosis [47]. There is evidence that angiotensin converting enzyme (ACE) inhibitors and angiotensin II type I (AT1) receptor blockers may have beneficial effects on oxidative stress, in addition to their antihypertensive properties. Statins, in addition to improving lipid profiles, may also lower oxidative stress [47,48]. Future antioxidant therapies need to be more specific in targeting the site of action, be devoid of deleterious effects on other signalling pathways, and be targeted to a specific reactive oxygen species (ROS) or cellular compartment [49-51]. Factors responsible for the disappointing and discrepant results from observational and clinical studies on the relationship between antioxidant vitamins and CVD may include differences in the patients’ gender, age, body weight, duration of treatment, vitamin supplement dosages. and dietary habits. It may be important to re-evaluate the selection of foods rich in antioxidant compounds rather than the selection of supplements of these substances [52-54]. Acknowledgements The authors thank Ray Pizzuto (English Medical Unit, G. D’Annuzio University, Chieti, Italy) for help in editing this article. References 1.

2.

3. 4. 5.

Davies MJ, Richardson PJ, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993;69:337-381. Davies M. Acute coronary thrombosis: the role of plaque disruption and its initiation and prevention. Eur Heart J 1995;16: 3-7. Davies M. The composition of coronary artery plaque. NEJM 1997;336:1312-1313. Batter A. European heart survey of acute coronary syndromes. Eur Heart J 2002;23:1190-1201. Murabito JM, Evans JC, Larson MG, Levy D. Prognosis after the onset of coronary heart disease. An investigation

94

6.

7.

8.

9.

10.

11.

12.

13. 14.

15.

16. 17.

18.

19.

20.

21.

Annals of Clinical & Laboratory Science, vol. 37, no. 1, 2007 of differences in outcome between the sexes according to initial coronary disease presentation. Circulation 1993;88:2548-2555. Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997;349:1269-1276. Harrison RA, Holt D, Pattison DJ, Elton PJ. Are those in need taking dietary supplements? A survey of 21923 adults. Br J Nutr 2004;91:617-623. Hasnian BI, Moradian AD. Recent trials of antioxidant therapy: what should we be telling our patients? Cleve Clin J Med 2004;71:327:334. Ferrari R, Guardigli G, Mele D, Percoco GF, Ceconi G, Curello S. Oxidative stress during myocardial ischaemia and heart failure. Curr Pharm Des 2004;10:1699-1711. Violi F, Loffredo L, Musella L, Marcoccia A. Should antioxidant status be considered in interventional trials with antioxidants? Heart 2004;90:598-602. Kuller LH, Taven ND, Rutan GH, Perper JA, Ives DG. Marked decline of coronary heart disease mortality in 35-44-year-old white men in Allegheny County, Pennsylvania. Circulation 1989;80 261-266. Schroder S. Is supplementation with antioxidants effective in the treatment of atherosclerosis? Med Wochenschr 2004;129:321-326. Monteleone CA, Sherman AR. Nutrition and asthma. Arch Intern Med 1997;157:23-34. Rock E, Winklhofer-Roob BM, Ribalta J, Scotter M, Vasson MP, Brtko J, Brigelius-Flohe R, Bronner A, Azais-Braesco V. Vitamin A, vitamin E and carotenoid status and metabolism during ageing: functional and nutritional consequences (VITAGE PROJECT). Nutr Metab Cardiovasc Dis 2001;11:70-73. Gordon T, Kannel WB. Multiple risk functions for predicting coronary heart disease: the concept, accuracy and application. Am Heart J 1982;103:1031-1039. Ross R. The pathogenesis of atherosclerosis–an update. NEJM 1986;314:488-500. Riccioni G, D’Orazio N. The role of selenium, zinc and antioxidant vitamin supplementation in the treatment of bronchial asthma: adjuvant therapy or not? Exp Opin Invest Drugs 2005;14:9-17. Kushi LH, Folsom AR, Prineas RJ, Mink PJ, Wu Y, Bostick RM. Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. NEJM 1996;334:1156-1162. Hennekens CH, Albert CM, Godfried SL, Gaziano JM, Buring JE. Physicians Health Study. Lack of effect of long term supplementation with β-carotene on the incidence of malignant neoplasm and cardiovascular disease. NEJM 1996;334:1145-1149. Hak AE, Stampfer MJ, Campois H, Sesso HD, Gaziano M, Willett W, Ma J. Plasma carotenoids and tocopherols and risk of myocardial infarction in a low risk population of US male physicians. Circulation 2003;108:802-807. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL, Valanis B, Williams JH, Barnhart S, Hammar. Beta-carotene and retinol efficacy trial (CARET). Effects of a

22.

23.

24.

25.

26. 27.

28.

29.

30.

31.

32. 33.

34.

35. 36. 37.

38.

combination of β-carotene and vitamin A on lung cancer and cardiovascular disease. NEJM 1996;334:1150-1155. Rapola JM, Virtamo J, Ripatti S, Huttunen JK, Albanes D, Taylor PR, Heinonen OP. Alpha-tocopherol betacarotene cancer prevention study (ATBC). Randomized trial of α–tocopherol and β-carotene supplements on incidence of major coronary events in men with previous MI. Lancet 1997;349:1715-1720. Enstrom JE. Vitamin C intake and mortality among sample of U.S. population. Epidemiology 1992;3:194202. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. NEJM 1993;328:1450-1456. Joshipura KJ, Hu FB, Manson JE, Stampfer MJ, Rimm EB, Speizer FE, Coldits G, Ascherio A, Rosner B, Spiegelman D, Willett WC. The effect of fruit and vegetable intake on risk for coronary heart disease. Ann Int Med 2001;134:1106-1114. Diaz MN. Antioxidants and atherosclerotic heart disease. NEJM 1997;337:408-416. Martin DU, Pan RC. Prevention of cardiovascular and degenerative diseases: aspirin, statins, or vitamins? Rev Med Suisse Rom 2003;123:175-181. Riemersma RA, Wood DA, Macintyr CC, Elton RA, Gey KF, Oliver MF. Anti-oxidants and pro-oxidants in coronary heart disease. Lancet 1991;337:677-679. Kinlay S; Berhendt D, Fang JC, Delagrange G, Morrow J, Witztum JL, Rifai N, Selwyn AP, Creager MA, Ganz P. Long-term effect of combined vitamins E and C on coronary and peripheral endothelial function. J Am Coll Cardiol 2004;43:629-634. Bloem MW, Wedel M, Egger RJ. Mild vitamin A deficiency and risk of respiratory tract diseases and diarrhea in preschool and school children in northeastern Thailand. Am J Epidemiol 1990:131:332-339. Filteau SM, Morris S, Abbott RA. Influence of morbidity on serum retinol of children in a community-based study in northern Ghana. Am J Clin Nutr 1993;58:192197. Zachman RD. Role of vitamin A in lung development. J Nutr 1995;125:1634S-1638S. Picado C, Deulofeu R, Lleonart R. Dietary micronutrients/antioxidants and their relationship with bronchial asthma severity. Allergy 2001:56:43-49. McDermoth JH. Antioxidant nutrients: current dietary recommendations and research update. J Am Pharm Assoc 2000;40:785-799. Soutar A, Seaton A, Brown K. Bronchial reactivity and dietary antioxidants. Thorax 1997;52:166-170. Hatch GE. Asthma, inhaled oxidants, and dietary antioxidants. Am J Clin Nutr 1995; 61:625S-630S. Kelly FJ, Mudway I, Blomberg A, Frew A, Sandstrom T. Altered lung antioxidant in patients with mild asthma. Lancet 1999;354:482-483. Stephens NG, Parson A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease:

Antioxidant vitamin supplementation in cardiovascular diseases 95

39.

40.

41.

42.

43.

44.

45.

46.

Cambridge heart antioxidant study (CHAOS) Lancet 1996;347;781-786. Kawachi I, Colditz GA, Ascherio A, Rimm EB, Giovannucci E, Stampfer MJ, Willett WC. Prospective study of phobic anxiety and risk of coronary heart disease in men. Circulation 1994;89:1992-1997. Ellis NI, Lloyd B, Lloyd RS, Clayton BE. Selenium and vitamin E in relation to risk factors for coronary heart disease. J Clin Pathol 1984;37:200-206. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, Knecht A, Weissgarten Y, Fainaru M, Green M. Secondary prevention using antioxidants of cardiovascular disease in endstage renal disease: SPACE. Eur Heart J 2000;21:S458. Negri E, La Vecchia C, Nobili A, D’Avanzo B, Bechi S. Cigarette smoking and acute myocardial infarction. A case-control study from the GISSI-2 trial. Eur J Epidemiol 1994;10:361-366. The Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high risk patients. NEJM 2000;342:154-160. Stanner SA, Hughes J, Kelly CN, Buttriss J. A review of the epidemiological evidence for the “antioxidant hypothesis.” Public Health Nutr 2004;7:407-422. U.S. Preventive Services Task Force. Routine vitamin supplementation to prevent cancer and cardiovascular disease. Nutr Clin Care 2003;6:102-107. Shishehbor MH, Hazen SL. Antioxidant studies need a change of direction. Clev Clin J Med 2004;71:285-288.

47. Ng DS. The role of statins in oxidative stress and cardiovascular disease. Curr Drug Targets Cardiovasc Haematol Disord 2005;5:165-175. 48. Hamilton CA, Miller WH, Al-Benna S, Brosnan MJ, Drummond RD, McBride MW, Dominiczak AF. Strategies to reduce oxidative stress in cardiovascular disease. Clin Sci 2004;106:219-234. 49. Lawlor DA, Davey Smith G, Kundu D, Bruckdorfer KR, Ebrahim S. Those confounded vitamins: what can be learned from the differences between observational versus randomized trial evidence? Lancet 2004;363:16601661. 50. Cozma LS. The role of antioxidants therapy in cardiovascular disease. Curr Opin Lipidol 2004;15:369-371. 51. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001,104:365372. 52. Kris-Etherton PM, Lefevre M, Beecher GR, Gross MD, Keen CL, Etherton TD. Bioactive compounds in nutrition and health-research methodologies for establishing biological function: the antioxidant and anti-inflammatory effects of flavonoids on atherosclerosis. Ann Rev Nutr 2004;24:511-538. 53. Sesso HD, Buring JE, Nokus EP, Graziano JM. Plasma lycopene, other carotenoids, and retinol and risk of cardiovascular disease in women. Am J Clin Nutr 2004;79:47-53. 54. Abudu N, Miller JJ, Attaelmannan M, Levinson SS. Vitamins in human arteriosclerosis with emphasis on vitamin C and vitamin E. Clin Chim Acta 2004;339:1125.

Suggest Documents